AU782880B2 - High order nucleic acid based structures - Google Patents

High order nucleic acid based structures Download PDF

Info

Publication number: AU782880B2
Authority: AU; Australia
Prior art keywords: nucleic acid; molecules; poly; molecule; library
Prior art date: 1999-11-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU20001/01A

Other languages

English (en)

Other versions

AU2000101A (en

Inventor

Frank J Carr

Graham Carter

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Patent GmbH

Original Assignee

Merck Patent GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-13

Filing date

2000-11-13

Publication date

2005-09-08

1999-11-13 Priority claimed from GBGB9926810.4A external-priority patent/GB9926810D0/en

2000-05-10 Priority claimed from GB0011126A external-priority patent/GB0011126D0/en

2000-11-13 Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH

2001-05-30 Publication of AU2000101A publication Critical patent/AU2000101A/en

2005-09-08 Application granted granted Critical

2005-09-08 Publication of AU782880B2 publication Critical patent/AU782880B2/en

2020-11-13 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

150000007523 nucleic acids Chemical class 0.000 title claims description 105
102000039446 nucleic acids Human genes 0.000 title claims description 87
108020004707 nucleic acids Proteins 0.000 title claims description 87
108091033319 polynucleotide Proteins 0.000 claims description 33
102000040430 polynucleotide Human genes 0.000 claims description 33
125000003729 nucleotide group Chemical group 0.000 claims description 11
230000003993 interaction Effects 0.000 claims description 9
239000002773 nucleotide Substances 0.000 claims description 7
239000011159 matrix material Substances 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
108010001267 Protein Subunits Proteins 0.000 claims description 2
108020004414 DNA Proteins 0.000 description 55
230000027455 binding Effects 0.000 description 29
108090000623 proteins and genes Proteins 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 19
235000018102 proteins Nutrition 0.000 description 16
238000000034 method Methods 0.000 description 14
210000004027 cell Anatomy 0.000 description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
238000000137 annealing Methods 0.000 description 11
108091034117 Oligonucleotide Proteins 0.000 description 9
239000011324 bead Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
230000000694 effects Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000003752 polymerase chain reaction Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000003814 drug Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000004048 modification Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
102000053602 DNA Human genes 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
102000010789 Interleukin-2 Receptors Human genes 0.000 description 5
108010038453 Interleukin-2 Receptors Proteins 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
108010043277 recombinant soluble CD4 Proteins 0.000 description 5
GKBMIFPNPOSTHB-BJBKLNMKSA-N recombinant soluble cd4 Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GKBMIFPNPOSTHB-BJBKLNMKSA-N 0.000 description 5
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 5
229960003766 thrombin (human) Drugs 0.000 description 5
108090000190 Thrombin Proteins 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000035602 clotting Effects 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229960004072 thrombin Drugs 0.000 description 4
108091023037 Aptamer Proteins 0.000 description 3
206010053567 Coagulopathies Diseases 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
239000003656 tris buffered saline Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
229940039227 diagnostic agent Drugs 0.000 description 2
239000000032 diagnostic agent Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000012634 fragment Substances 0.000 description 2
102000034238 globular proteins Human genes 0.000 description 2
108091005896 globular proteins Proteins 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
241000894007 species Species 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
210000003956 transport vesicle Anatomy 0.000 description 2
238000011282 treatment Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
HRSBDXXXHGAUJF-QJPTWQEYSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-pent-1-ynylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C#CCCC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 HRSBDXXXHGAUJF-QJPTWQEYSA-N 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
102100033943 Basic salivary proline-rich protein 2 Human genes 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
108091008102 DNA aptamers Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
102100030011 Endoribonuclease Human genes 0.000 description 1
108010093099 Endoribonucleases Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
101001068639 Homo sapiens Basic salivary proline-rich protein 2 Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101001098256 Homo sapiens Lysophospholipase Proteins 0.000 description 1
101000983077 Homo sapiens Phospholipase A2 Proteins 0.000 description 1
101001096022 Homo sapiens Phospholipase B1, membrane-associated Proteins 0.000 description 1
102000009438 IgE Receptors Human genes 0.000 description 1
108010073816 IgE Receptors Proteins 0.000 description 1
108010063678 Indole-3-Glycerol-Phosphate Synthase Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
102100030856 Myoglobin Human genes 0.000 description 1
108010062374 Myoglobin Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
241000733322 Platea Species 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
241000183024 Populus tremula Species 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108091008103 RNA aptamers Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
230000004913 activation Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000006917 intersubunit interaction Effects 0.000 description 1
238000012804 iterative process Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000001455 metallic ions Chemical class 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
-1 tetrazolium compound Chemical class 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
GOMLCFUVZKLQCO-HTLAMOOLSA-N thrombin aptamer Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)[C@@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 GOMLCFUVZKLQCO-HTLAMOOLSA-N 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013519 translation Methods 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Crystallography & Structural Chemistry (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AU20001/01A 1999-11-13 2000-11-13 High order nucleic acid based structures Ceased AU782880B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB9926810		1999-11-13
GBGB9926810.4A GB9926810D0 (en)	1999-11-13	1999-11-13	High order nucleic acid-based structures
GB0011126		2000-05-10
GB0011126A GB0011126D0 (en)	2000-05-10	2000-05-10	High order nucleic acid-based structures
PCT/EP2000/011197 WO2001036624A1 (en)	1999-11-13	2000-11-13	High order nucleic acid based structures

Publications (2)

Publication Number	Publication Date
AU2000101A AU2000101A (en)	2001-05-30
AU782880B2 true AU782880B2 (en)	2005-09-08

Family

ID=26244234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU20001/01A Ceased AU782880B2 (en)	1999-11-13	2000-11-13	High order nucleic acid based structures

Country Status (16)

Country	Link
EP (1)	EP1228201A1 (cs)
JP (1)	JP2003522524A (cs)
KR (1)	KR20020059727A (cs)
CN (1)	CN1390253A (cs)
AU (1)	AU782880B2 (cs)
BR (1)	BR0015484A (cs)
CA (1)	CA2391084A1 (cs)
CZ (1)	CZ20021472A3 (cs)
HK (1)	HK1052529A1 (cs)
HU (1)	HUP0203914A2 (cs)
MX (1)	MXPA02004727A (cs)
NO (1)	NO20022231D0 (cs)
PL (1)	PL358811A1 (cs)
RU (1)	RU2002113755A (cs)
SK (1)	SK6042002A3 (cs)
WO (1)	WO2001036624A1 (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2487300A (en)	1998-12-31	2000-07-31	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1411770A4 (en)	2001-07-05	2006-05-10	Chiron Corp	POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
JP2014525921A (ja) *	2011-08-05	2014-10-02	プレジデントアンドフェローズオブハーバードカレッジ	核酸ナノテクノロジー及びマイクロテクノロジーに関する組成物及び方法
WO2014018675A1 (en)	2012-07-24	2014-01-30	President And Fellows Of Harvard College	Self-assembly of nucleic acid nanostructures
WO2014074597A1 (en)	2012-11-06	2014-05-15	President And Fellows Of Harvard College	Compositions and methods relating to complex nucleic acid nanostructures
WO2015070080A2 (en) *	2013-11-08	2015-05-14	Dana-Farber Cancer Institute, Inc.	Nucleic acid nanostructures for in vivo agent delivery
JP2017523594A (ja)	2014-05-22	2017-08-17	プレジデントアンドフェローズオブハーバードカレッジ	スケーラブルな核酸をベースにしたナノファブリケーション
EP3426598B1 (en)	2016-03-11	2021-07-28	Children's Medical Center Corporation	Nucleic acid nanoswitch catenanes
EP3494124B1 (en)	2016-08-02	2022-03-09	President and Fellows of Harvard College	Crisscross cooperative self-assembly
CN110711254B (zh) *	2018-07-12	2022-07-26	百药智达（北京）纳米生物技术有限公司	核酸纳米颗粒及包含其的药物组合物
TWI743518B (zh) *	2018-07-12	2021-10-21	大陸商百藥智達（北京）納米生物技術有限公司	核酸奈米顆粒、包含其的藥物組合物、含阿霉素的藥物及其製備方法
CN110960534B (zh) *	2018-09-30	2022-07-26	百药智达（北京）纳米生物技术有限公司	含五氟尿嘧啶的药物、其制备方法、药物组合物及其应用
CN110960536B (zh) *	2018-09-30	2022-07-26	百药智达（北京）纳米生物技术有限公司	含阿司匹林的药物、其制备方法、药物组合物及应用
CN110960530B (zh) *	2018-09-30	2022-07-22	百药智达（北京）纳米生物技术有限公司	含他克林的药物、其制备方法、药物组合物及其应用
CN110960542B (zh) *	2018-09-30	2022-07-26	百药智达（北京）纳米生物技术有限公司	含吡柔比星的药物、其制备方法、药物组合物及其应用
CN110960690B (zh) *	2018-09-30	2022-07-22	百药智达（北京）纳米生物技术有限公司	含表柔比星的药物、其制备方法、药物组合物及其应用
CN111053765B (zh) *	2018-10-16	2022-07-26	百药智达（北京）纳米生物技术有限公司	含紫杉醇的药物、其制备方法、药物组合物及应用
CN111068065B (zh) *	2018-10-22	2022-07-26	百药智达（北京）纳米生物技术有限公司	含奥沙利铂的药物、其制备方法、药物组合物及其应用
CN111084887B (zh) *	2018-10-23	2022-07-22	百药智达（北京）纳米生物技术有限公司	含黄酮的药物、其制备方法、药物组合物及应用
CN111096965B (zh) *	2018-10-29	2022-07-26	百药智达（北京）纳米生物技术有限公司	含双氢青蒿素的药物、其制备方法、药物组合物及其应用
US12268748B2 (en)	2019-04-10	2025-04-08	President And Fellows Of Harvard College	Nucleic acid nanostructures crosslinked with oligolysine
WO2020247724A1 (en)	2019-06-07	2020-12-10	Dana-Farber Cancer Institute, Inc.	Dna nanostructure-based vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992012164A1 (en) *	1991-01-10	1992-07-23	New York University	Multiply connected, three-dimensional nucleic acid structures
WO1993012244A1 (en) *	1991-12-12	1993-06-24	New York University	Construction of geometrical objects from polynucleotides
WO1997041142A1 (en) *	1996-04-26	1997-11-06	New York University	Nanoconstructions of geometrical objects and lattices from antiparallel nucleic acid double crossover molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0151631A1 (en) *	1983-08-03	1985-08-21	The Research Foundation Of State University Of New York	Nucleic acid branched junctions with precisely defined migrational mobility

2000
- 2000-11-13 AU AU20001/01A patent/AU782880B2/en not_active Ceased
- 2000-11-13 PL PL00358811A patent/PL358811A1/xx unknown
- 2000-11-13 SK SK604-2002A patent/SK6042002A3/sk not_active Application Discontinuation
- 2000-11-13 BR BR0015484-9A patent/BR0015484A/pt not_active IP Right Cessation
- 2000-11-13 WO PCT/EP2000/011197 patent/WO2001036624A1/en not_active Ceased
- 2000-11-13 KR KR1020027006140A patent/KR20020059727A/ko not_active Withdrawn
- 2000-11-13 MX MXPA02004727A patent/MXPA02004727A/es unknown
- 2000-11-13 HU HU0203914A patent/HUP0203914A2/hu unknown
- 2000-11-13 EP EP00983130A patent/EP1228201A1/en not_active Withdrawn
- 2000-11-13 JP JP2001538503A patent/JP2003522524A/ja active Pending
- 2000-11-13 CA CA002391084A patent/CA2391084A1/en not_active Abandoned
- 2000-11-13 CZ CZ20021472A patent/CZ20021472A3/cs unknown
- 2000-11-13 CN CN00815433A patent/CN1390253A/zh active Pending
- 2000-11-13 HK HK03104743.9A patent/HK1052529A1/zh unknown
- 2000-11-13 RU RU2002113755/04A patent/RU2002113755A/ru unknown
2002
- 2002-05-10 NO NO20022231A patent/NO20022231D0/no unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992012164A1 (en) *	1991-01-10	1992-07-23	New York University	Multiply connected, three-dimensional nucleic acid structures
WO1993012244A1 (en) *	1991-12-12	1993-06-24	New York University	Construction of geometrical objects from polynucleotides
WO1997041142A1 (en) *	1996-04-26	1997-11-06	New York University	Nanoconstructions of geometrical objects and lattices from antiparallel nucleic acid double crossover molecules

Also Published As

Publication number	Publication date
KR20020059727A (ko)	2002-07-13
SK6042002A3 (en)	2002-12-03
WO2001036624A1 (en)	2001-05-25
CN1390253A (zh)	2003-01-08
BR0015484A (pt)	2002-07-02
EP1228201A1 (en)	2002-08-07
HUP0203914A2 (en)	2003-03-28
MXPA02004727A (es)	2002-08-30
AU2000101A (en)	2001-05-30
CZ20021472A3 (cs)	2002-07-17
PL358811A1 (en)	2004-08-23
RU2002113755A (ru)	2004-01-10
HK1052529A1 (zh)	2003-09-19
NO20022231L (no)	2002-05-10
JP2003522524A (ja)	2003-07-29
CA2391084A1 (en)	2001-05-25
NO20022231D0 (no)	2002-05-10

Publication	Publication Date	Title
AU782880B2 (en)	2005-09-08	High order nucleic acid based structures
Ishikawa et al.	2013	RNA tectonics (tectoRNA) for RNA nanostructure design and its application in synthetic biology
US8440811B2 (en)	2013-05-14	DNA nanostructures that promote cell-cell interaction and use thereof
AU2009200036B2 (en)	2012-07-26	Modulators of pharmacological agents
JP2024029136A (ja)	2024-03-05	Ｄ因子を阻害するための組成物および方法
Goringer et al.	2008	Post-SELEX chemical optimization of a trypanosome-specific RNA aptamer
AU2002312059A1 (en)	2003-05-08	Modulators of pharmacological agents
US20120190732A1 (en)	2012-07-26	Multifunctional Aptamer-Nucleic Acid Nanostructures for Tumor-Targeted Killing
CN103403189A (zh)	2013-11-20	用于稳定的多价RNA纳米颗粒中的pRNA多价连接域
TW202600825A (zh)	2026-01-01	抑制lpa之基因表現之組合物及方法
JP2006516151A (ja)	2006-06-22	改良された薬力学的特性を有する多価アプタマー治療剤ならびにそれらの作製方法および使用法
Kopylov et al.	2000	Combinatorial chemistry of nucleic acids: SELEX
CN102459599A (zh)	2012-05-16	糖蛋白vi的核酸调节剂
Nakamura et al.	2012	RNA plasticity and selectivity applicable to therapeutics and novel biosensor development
JP2011092138A (ja)	2011-05-12	血管内皮細胞増殖因子結合性アプタマー
Otte et al.	2022	Nucleic acid aptamers: From basic research to clinical applications
Zavyalova et al.	2018	DNA aptamer-based molecular nanoconstructions and nanodevices for diagnostics and therapy
ZA200204728B (en)	2003-11-25	High order nucleic acid based structures.
JP7264487B2 (ja)	2023-04-25	キマーゼに対するアプタマー及びその使用
AU2012244176B8 (en)	2016-01-28	Modulators of pharmacological agents
Iric	2020	Assembly of DNA-encapsulated lipid bilayers and their application to studies of GPCRs
AU2012244176B2 (en)	2015-09-17	Modulators of pharmacological agents
JP2025152676A (ja)	2025-10-10	フラビウイルスに対するアプタマー及びその使用
Polisky	1998	Progress towards Therapeutic Application of SELEX-derived Aptamers
WO2020204151A1 (ja)	2020-10-08	Ｆｇｆ９に対するアプタマー及びその使用